CZ2006533A3 - Amorfní ritonavir, způsoby jeho přípravy, jeho použití a farmaceutická kompozice ho obsahující - Google Patents

Amorfní ritonavir, způsoby jeho přípravy, jeho použití a farmaceutická kompozice ho obsahující

Info

Publication number
CZ2006533A3
CZ2006533A3 CZ2006533A CZ2006533A CZ2006533A3 CZ 2006533 A3 CZ2006533 A3 CZ 2006533A3 CZ 2006533 A CZ2006533 A CZ 2006533A CZ 2006533 A CZ2006533 A CZ 2006533A CZ 2006533 A3 CZ2006533 A3 CZ 2006533A3
Authority
CZ
Czechia
Prior art keywords
preparation
methods
pharmaceutical composition
amorphous ritonavir
ritonavir
Prior art date
Application number
CZ2006533A
Other languages
English (en)
Other versions
CZ307116B6 (cs
Inventor
John F Bauer
Azita Saleki-Gerhardt
Bikshandarkoil A Narayanan
Sanjay R Chemburkar
Ketan Patel
Harry O Spiwek
Philip E Bauer
Kimberley A Allen
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26817251&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CZ2006533(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of CZ2006533A3 publication Critical patent/CZ2006533A3/cs
Publication of CZ307116B6 publication Critical patent/CZ307116B6/cs

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28Radicals substituted by nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
CZ2006-533A 1998-07-20 1999-07-19 Amorfní ritonavir, způsoby jeho přípravy, jeho použití a farmaceutická kompozice ho obsahující CZ307116B6 (cs)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11934598A 1998-07-20 1998-07-20
US32609399A 1999-06-04 1999-06-04

Publications (2)

Publication Number Publication Date
CZ2006533A3 true CZ2006533A3 (cs) 2001-05-16
CZ307116B6 CZ307116B6 (cs) 2018-01-24

Family

ID=26817251

Family Applications (2)

Application Number Title Priority Date Filing Date
CZ2006-533A CZ307116B6 (cs) 1998-07-20 1999-07-19 Amorfní ritonavir, způsoby jeho přípravy, jeho použití a farmaceutická kompozice ho obsahující
CZ20010203A CZ298188B6 (cs) 1998-07-20 1999-07-19 Krystalický polymorf ritonaviru a zpusob jeho prípravy

Family Applications After (1)

Application Number Title Priority Date Filing Date
CZ20010203A CZ298188B6 (cs) 1998-07-20 1999-07-19 Krystalický polymorf ritonaviru a zpusob jeho prípravy

Country Status (30)

Country Link
EP (4) EP2298751A3 (cs)
JP (4) JP4815050B2 (cs)
KR (3) KR100853371B1 (cs)
CN (5) CN1310715B (cs)
AR (5) AR019431A1 (cs)
AT (3) ATE534636T1 (cs)
AU (1) AU768207B2 (cs)
BG (4) BG65150B1 (cs)
BR (1) BR9912010A (cs)
CA (3) CA2510949C (cs)
CO (1) CO5090830A1 (cs)
CY (2) CY1111600T1 (cs)
CZ (2) CZ307116B6 (cs)
DE (2) DE69940616D1 (cs)
DK (3) DK1097148T3 (cs)
ES (3) ES2214038T3 (cs)
HK (2) HK1037918A1 (cs)
HU (3) HU227540B1 (cs)
ID (1) ID27996A (cs)
IL (4) IL140492A0 (cs)
MY (2) MY145265A (cs)
NO (2) NO318385B1 (cs)
NZ (2) NZ522690A (cs)
PL (2) PL194710B1 (cs)
PT (3) PT2017269E (cs)
SI (3) SI1418174T1 (cs)
SK (3) SK286388B6 (cs)
TR (1) TR200100171T2 (cs)
TW (3) TWI271400B (cs)
WO (1) WO2000004016A2 (cs)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6894171B1 (en) 1998-07-20 2005-05-17 Abbott Laboratories Polymorph of a pharmaceutical
MY145265A (en) * 1998-07-20 2012-01-13 Abbott Lab Amorphous ritonavir
JP4753511B2 (ja) * 1999-06-04 2011-08-24 アボット・ラボラトリーズ 改良された医薬製剤
CA2448438A1 (en) * 2001-05-25 2002-12-05 Abbott Laboratories Soft elastic capsules comprising ritonavir and/or lopinavir
AR037797A1 (es) * 2001-12-12 2004-12-01 Tibotec Pharm Ltd Combinacion de inhibidores de proteasa dependientes del citocromo p450
US7205413B2 (en) 2002-05-03 2007-04-17 Transform Pharmaceuticals, Inc. Solvates and polymorphs of ritonavir and methods of making and using the same
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
BRPI0401742B8 (pt) 2004-05-13 2021-05-25 Cristalia Produtos Quim Farmaceuticos Ltda composto análogo do ritonavir útil como inibidor de protease retroviral, preparação do composto análogo do ritonavir e composição farmacêutica do composto análogo do ritonavir
US20080312300A1 (en) * 2005-05-30 2008-12-18 Yoginder Pal Sachdeva Processes for the Preparation of Stable Polymorphic Form I of Ritonavir
US20100099885A1 (en) * 2006-10-03 2010-04-22 Mukesh Kumar Sharma Process for the preparation of form i and form ii of ritonavir
CN102898398B (zh) * 2011-07-27 2015-01-14 上海迪赛诺药业有限公司 一种制备i型利托那韦多晶型结晶的方法
EP2822554B1 (en) 2012-03-07 2016-05-18 ratiopharm GmbH Dosage form comprising lopinavir and ritonavir
EP2822553B1 (en) 2012-03-07 2016-05-18 ratiopharm GmbH Dosage form comprising non-crystalline lopinavir and crystalline ritonavir
MX2016002560A (es) 2013-08-29 2016-10-26 Teva Pharma Forma de dosificacion unitaria que comprende emtricitabina, tenofovir, darunavir y ritonavir y un comprimido monolitico que comprende darunavir y ritonavir.
TW201622731A (zh) 2014-04-08 2016-07-01 泰瓦藥品工業有限公司 包含恩曲他濱(Emtricitabine)、替諾福韋(Tenofovir)、地瑞那韋(Darunavir)及利托那韋(Ritonavir)之單位劑型以及包含地瑞那韋及利托那韋之單層錠劑
CN106749085B (zh) * 2016-12-23 2019-05-24 东北制药集团股份有限公司 一种制备利托那韦的方法
EP3569225A1 (en) 2018-05-18 2019-11-20 Pharmaceutical Oriented Services Ltd Solid dispersion containing ritonavir
RU2759544C1 (ru) * 2021-01-29 2021-11-15 Общество с ограниченной ответственностью "АМЕДАРТ" Твёрдая фармацевтическая композиция для изготовления перорального терапевтического средства для профилактики и/или лечения ВИЧ-инфекции

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5354866A (en) 1989-05-23 1994-10-11 Abbott Laboratories Retroviral protease inhibiting compounds
US5552558A (en) 1989-05-23 1996-09-03 Abbott Laboratories Retroviral protease inhibiting compounds
PT727419E (pt) * 1992-12-29 2002-08-30 Abbott Lab Compostos intermediarios para a preparacao de inibidores da protease retroviral
IL110752A (en) 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
US5559158A (en) 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
US5491253A (en) 1993-10-22 1996-02-13 Abbott Laboratories Process for the preparation of a substituted 2,5-diamino-3-hydroxyhexane
IL111991A (en) 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
US5567823A (en) 1995-06-06 1996-10-22 Abbott Laboratories Process for the preparation of an HIV protease inhibiting compound
US6037157A (en) * 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US6160122A (en) 1996-06-28 2000-12-12 Abbott Laboratories Process for the preparation of a disubstituted thiazole
ZA9710071B (en) 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.
MY145265A (en) * 1998-07-20 2012-01-13 Abbott Lab Amorphous ritonavir
DE19856432A1 (de) * 1998-12-08 2000-06-15 Basf Ag Nanopartikuläre Kern-Schale Systeme sowie deren Verwendung in pharmazeutischen und kosmetischen Zubereitungen
JP4753511B2 (ja) * 1999-06-04 2011-08-24 アボット・ラボラトリーズ 改良された医薬製剤

Also Published As

Publication number Publication date
MY145265A (en) 2012-01-13
EP1418174A2 (en) 2004-05-12
NZ522690A (en) 2004-04-30
WO2000004016A2 (en) 2000-01-27
TR200100171T2 (tr) 2001-05-21
IL187181A0 (en) 2008-02-09
NO327320B1 (no) 2009-06-08
SK287586B6 (sk) 2011-03-04
ES2322759T3 (es) 2009-06-26
SK287381B6 (sk) 2010-08-09
AU768207B2 (en) 2003-12-04
PL194710B1 (pl) 2007-06-29
IL140492A (en) 2010-12-30
WO2000004016A3 (en) 2000-03-30
AU5003799A (en) 2000-02-07
CA2337846A1 (en) 2000-01-27
SI1097148T1 (en) 2004-10-31
EP2017269B1 (en) 2011-11-23
CA2674800A1 (en) 2000-01-27
CN101966180A (zh) 2011-02-09
CY1111600T1 (el) 2015-10-07
CO5090830A1 (es) 2001-10-30
SK922001A3 (en) 2001-07-10
EP2017269A8 (en) 2009-09-30
HU230150B1 (hu) 2015-09-28
CA2337846C (en) 2006-02-21
CZ298188B6 (cs) 2007-07-18
PT1097148E (pt) 2004-05-31
JP2010270135A (ja) 2010-12-02
HU0800266D0 (en) 2008-06-30
CY1112139T1 (el) 2015-11-04
CN102153524A (zh) 2011-08-17
ES2372990T3 (es) 2012-01-30
NO20010298L (no) 2001-01-18
PT1418174E (pt) 2009-06-08
DE69940616D1 (de) 2009-04-30
NZ509125A (en) 2003-02-28
CN1310715B (zh) 2010-11-03
CA2510949A1 (en) 2000-01-27
EP2298751A2 (en) 2011-03-23
JP2017061475A (ja) 2017-03-30
EP2017269A9 (en) 2009-10-14
SK286388B6 (sk) 2008-09-05
KR20040081137A (ko) 2004-09-20
NO20042393L (no) 2001-01-18
AR049658A2 (es) 2006-08-23
BG65150B1 (bg) 2007-04-30
PL213978B1 (pl) 2013-05-31
AR019431A1 (es) 2002-02-20
ID27996A (id) 2001-05-03
EP2298751A3 (en) 2011-08-17
EP1418174A3 (en) 2004-06-23
CN101259128A (zh) 2008-09-10
SI2017269T1 (sl) 2012-02-29
EP1097148A2 (en) 2001-05-09
HU229999B1 (en) 2015-04-28
NO318385B1 (no) 2005-03-14
HU227540B1 (en) 2011-08-29
BG105197A (en) 2001-10-31
BG65963B1 (bg) 2010-07-30
HK1121155A1 (en) 2009-04-17
EP1418174B1 (en) 2009-03-18
DK1418174T3 (da) 2009-05-18
NO20010298D0 (no) 2001-01-18
CN1310715A (zh) 2001-08-29
PT2017269E (pt) 2011-12-20
KR20010072003A (ko) 2001-07-31
PL348033A1 (en) 2002-05-06
TWI271400B (en) 2007-01-21
IL191582A0 (en) 2008-12-29
EP2017269A2 (en) 2009-01-21
KR20060118022A (ko) 2006-11-17
SI1418174T1 (sl) 2009-08-31
JP4815050B2 (ja) 2011-11-16
HK1037918A1 (en) 2002-02-22
AR044029A2 (es) 2005-08-24
ATE425974T1 (de) 2009-04-15
HUP0103823A2 (hu) 2002-02-28
DE69915628T2 (de) 2004-08-12
TW200716550A (en) 2007-05-01
KR100793046B1 (ko) 2008-01-10
CA2510949C (en) 2009-11-17
KR100853371B1 (ko) 2008-08-22
BG110080A (bg) 2008-11-28
CZ2001203A3 (en) 2001-05-16
DK2017269T3 (da) 2012-03-05
JP5732212B2 (ja) 2015-06-10
EP1097148B1 (en) 2004-03-17
JP2014074047A (ja) 2014-04-24
HUP0103823A3 (en) 2003-05-28
IL191582A (en) 2016-02-29
IL140492A0 (en) 2002-02-10
AR059763A2 (es) 2008-04-30
BG109682A (bg) 2007-03-30
TWI362382B (en) 2012-04-21
ATE261947T1 (de) 2004-04-15
BR9912010A (pt) 2001-04-10
CN1502613A (zh) 2004-06-09
ES2214038T3 (es) 2004-09-01
AR059764A2 (es) 2008-04-30
DK1097148T3 (da) 2004-04-26
DE69915628D1 (en) 2004-04-22
EP2017269A3 (en) 2009-06-10
HU0800267D0 (en) 2008-06-30
CZ307116B6 (cs) 2018-01-24
JP2002520410A (ja) 2002-07-09
KR100740796B1 (ko) 2007-07-20
MY121765A (en) 2006-02-28
ATE534636T1 (de) 2011-12-15
BG66140B1 (bg) 2011-07-29
TWI227713B (en) 2005-02-11
IL187181A (en) 2009-09-01

Similar Documents

Publication Publication Date Title
CZ20011518A3 (cs) Farmaceutický prostředek
HK1041224A1 (zh) 新的藥物製劑
IL138280A0 (en) 20-KETO-11β-ARYLSTERIODS, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND METHODS FOR THE PREPARATION THEREOF
PL351387A1 (en) Pharmaceutical composition
HK1121155A1 (en) A pharmaceutical composition comprising form ii crystalline ritonavir and a preparation thereof
HK1048999A1 (zh) 氮雜䓬吲衍生物,它們的製備和應用
AU5326100A (en) Pharmaceutical compositions and methods for use
PT1466615E (pt) Composição farmacêutica
AU2578701A (en) Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same
HUP0301333A3 (en) Pharmaceutical superdisintegrant, process for its preparation and its use
HUP0203597A3 (en) Pharmaceutical compositions containing zolmitriptan, process for their preparation and their use
AU5565099A (en) Pharmaceutical compositions and methods for use
PL343769A1 (en) Pharmaceutical composition
GB9818591D0 (en) Pharmaceutical composition
HK1046140A1 (zh) 固體藥劑
HUP0201629A3 (en) Pharmaceutical complex containing eletriptan and cyclodextrin-derivative, pharmaceutical composition containing it, process for its preparation and its use
GB9818927D0 (en) Pharmaceutical formulation
HK1044117B (zh) 藥物組合物
HUP0104544A3 (en) New pharmaceutical composition and the process for its preparation
ZA99168B (en) Pharmaceutical formulations and processes for their preparation.
GB9822333D0 (en) Pharmaceutical formulation
AU5483600A (en) Pharmaceutical materials and methods for their preparation and use
AU2880699A (en) Pharmaceutical compositions and methods for use
HUP0103569A3 (en) New medicament and process for its preparation
GB9817470D0 (en) Pharmaceutical formulation

Legal Events

Date Code Title Description
MK4A Patent expired

Effective date: 20190719